AstraZeneca Pharma India Limited — Updates, 14-08-2025: Press Release

AstraZeneca Pharma India (ASTRAZEN) delivered robust Q1 FY25-26 results. Revenue jumped 36% YoY to ₹526.31 Cr, with profit after tax hitting ₹55.83 Cr. Strong performance was seen in Oncology. Crucially, the company secured four new drug approvals for expanded indications of key treatments like Osimertinib (NSCLC), Trastuzumab Deruxtecan (breast cancer), and Benralizumab (EGPA). These approvals strengthen their product portfolio and reinforce leadership in critical therapy areas, setting the stage for future growth.